Comparison of Deuterium Metabolic Imaging with FDG PET in Alzheimer Disease

Background The approval of amyloid-targeting therapies has made it increasingly important to differentiate Alzheimer disease (AD) from other causes of dementia. Dysfunctional glucose metabolism is a recognized pathophysiological element in AD that may be visualized with spectroscopic MRI of deuterated glucose and its metabolites, also known as deuterium metabolic imaging (DMI). Purpose To explore the potential of DMI as a diagnostic tool for AD. Materials and Methods In this prospective cross-sectional study, participants with newly diagnosed AD and age-matched controls were recruited from April to October 2023. DMI was performed with a 3-T system equipped with a proton/deuterium head coil following oral consumption of 75 g of deuterated glucose. Clinical fluorodeoxyglucose (FDG) PET data were acquired from patient records for comparison. The predefined primary outcome, the ratio between lactate and glutamine plus glutamate (Glx) at DMI, was analyzed using age-corrected linear mixed-effect models. Results Ten participants with AD (mean age, 72 years ± 6 [SD]; six women) and five age-matched healthy controls (mean age, 68 years ± 7; four men) were included. The primary analysis revealed no evidence of a difference in the ratio of lactate to Glx between participants with AD and controls (<i>P</i> = .24 across all regions of interest). Exploratory analyses revealed that participants with AD had reduced signals for medial temporal lactate (0.7 ± 0.2 vs 0.5 ± 0.1, <i>P</i> = .04) and Glx (0.5 ± 0.03 vs 0.48 ± 0.05, <i>P</i> = .03) compared with controls. Finally, a strong correlation (<i>r</i> = 0.73) was observed between DMI and FDG PET. Conclusion This study did not find evidence to support a shift from oxidative to anaerobic metabolism in AD. Exploratory analyses revealed a decrease in glucose metabolism in the medial temporal lobe. In extension hereof, a similar distribution of low DMI metabolism and decreased FDG PET glucose uptake was observed. © RSNA, 2025 <i>Supplemental material is available for this article.</i> See also the article by Liu et al in this issue. See also the editorial by Port in this issue.

Authors

Institutions

Publication Details

Journal
Radiology
Published
2025-04-01
DOI
https://doi.org/10.1148/radiol.241808
Citations
7
Primary Topic
Medical Imaging Techniques and Applications
Type
article
Field-Weighted Citation Impact
9.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of Deuterium Metabolic Imaging with FDG PET in Alzheimer Disease

Per Borghammer, Nikolaj Bøgh, Janne Kaergaard Mortensen, Mattias Hedegaard Kristensen et al.
7 citations
Radiology
Medical Imaging Techniques and Applications
9.52
article

Comparison of Deuterium Metabolic Imaging with FDG PET in Alzheimer Disease

Per Borghammer, Nikolaj Bøgh, Janne Kaergaard Mortensen, Mattias Hedegaard Kristensen, Hanne Gottrup, Esben Søvsø Szocska Hansen, Christoffer Laustsen, Michael Væggemose, Jakob Udby Blicher, Malene Aastrup
article en
7 citations

Abstract

Background The approval of amyloid-targeting therapies has made it increasingly important to differentiate Alzheimer disease (AD) from other causes of dementia. Dysfunctional glucose metabolism is a recognized pathophysiological element in AD that may be visualized with spectroscopic MRI of deuterated glucose and its metabolites, also known as deuterium metabolic imaging (DMI). Purpose To explore the potential of DMI as a diagnostic tool for AD. Materials and Methods In this prospective cross-sectional study, participants with newly diagnosed AD and age-matched controls were recruited from April to October 2023. DMI was performed with a 3-T system equipped with a proton/deuterium head coil following oral consumption of 75 g of deuterated glucose. Clinical fluorodeoxyglucose (FDG) PET data were acquired from patient records for comparison. The predefined primary outcome, the ratio between lactate and glutamine plus glutamate (Glx) at DMI, was analyzed using age-corrected linear mixed-effect models. Results Ten participants with AD (mean age, 72 years ± 6 [SD]; six women) and five age-matched healthy controls (mean age, 68 years ± 7; four men) were included. The primary analysis revealed no evidence of a difference in the ratio of lactate to Glx between participants with AD and controls (<i>P</i> = .24 across all regions of interest). Exploratory analyses revealed that participants with AD had reduced signals for medial temporal lactate (0.7 ± 0.2 vs 0.5 ± 0.1, <i>P</i> = .04) and Glx (0.5 ± 0.03 vs 0.48 ± 0.05, <i>P</i> = .03) compared with controls. Finally, a strong correlation (<i>r</i> = 0.73) was observed between DMI and FDG PET. Conclusion This study did not find evidence to support a shift from oxidative to anaerobic metabolism in AD. Exploratory analyses revealed a decrease in glucose metabolism in the medial temporal lobe. In extension hereof, a similar distribution of low DMI metabolism and decreased FDG PET glucose uptake was observed. © RSNA, 2025 <i>Supplemental material is available for this article.</i> See also the article by Liu et al in this issue. See also the editorial by Port in this issue.

RadiologyVol. 315(1)
Aarhus University (DK), Aalborg University Hospital (DK), Aarhus University Hospital (DK)
Lundbeckfonden
Good health and well-being
Openalex Percentile: Top 2%
Medical Imaging Techniques and Applications
9.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.